Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients

DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE) --SeaStar Medical Holding Corporation (NASDAQ:ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces publication of a manuscript discussing the role of chronic dysregulated systemic inflammation in heart failure and the potential application of the adult Selective Cytopheretic Device, part of the Quelimmune product family, in enabling previously ineligible patients with severe disease to receive a left ventricular assist device (LVAD) or heart transplant in...